News

The Greater Bay Area International Clinical Trial Institute (GBAICTI) welcomes the Department of Health’s introduction of a “Priority Review Pathway” under the existing “1+” drug approval mechanism, and supports the Hospital Authority’s establishment of the Office for Introducing Innovative Drugs and Medical Devices (the Office). The “Priority Review Pathway” shortens the target review timeline for new drugs recommended by the Office, with cancer treatment drugs covered in the initial phase, from up to 150 working days to within 100 working days. This measure not only responds to the public’s demand for advanced treatment options, but also accelerates patients’ access to innovative medical outcomes while ensuring safety, efficacy, and quality, reflecting Hong Kong’s continued enhancement of its medical regulatory and healthcare systems.

As an institution dedicated to promoting medical innovation and consolidating Hong Kong’s position as an international clinical research hub, GBAICTI believes that strengthening synergy between regulatory efficiency and the healthcare system will help attract more innovative drug and clinical research projects to Hong Kong, further facilitating the translation of research outcomes and enhancing Hong Kong’s competitiveness in the regional and global biomedical innovation landscape. Looking ahead, GBAICTI will continue to work closely with the Government, healthcare institutions, and industry to promote the sustained development of the innovation ecosystem, bringing patients more timely, diverse, and high-quality treatment options.

Further details can be found in the press release: https://www.info.gov.hk/gia/general/202606/08/P2026060800398.htm?fontSize=1